Inhibition of Human Peptide Deformylase Disrupts Mitochondrial Function

por Escobar-Alvarez, Sindy, Gardner, Jeffrey, Sheth, Aneesh, Manfredi, Giovanni, Yang, Guangli, Ouerfelli, Ouathek, Heaney, Mark L., Scheinberg, David A.
Publicado em 2010

Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs

por Heaney, Mark L., Gardner, Jeffrey R., Karasavvas, Nicos, Golde, David W., Scheinberg, David A., Smith, Emily A., O’Connor, Owen A.
Publicado em 2008

A Self-Assembling Short Oligonucleotide Duplex Suitable for Pretargeting

por Mallikaratchy, Prabodhika, Gardner, Jeffery, Nordstrøm, Lars Ulrik R., Veomett, Nicholas J., McDevitt, Michael R., Heaney, Mark L., Scheinberg, David A.
Publicado em 2013

A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

por Mallikaratchy, Prabodhika R., Ruggiero, Alessandro, Gardner, Jeffrey R., Kuryavyi, Vitaly, Maguire, William F., Heaney, Mark L., McDevitt, Michael R., Patel, Dinshaw J., Scheinberg, David A.
Publicado em 2011

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: M...

por Lamanna, Nicole, Jurcic, Joseph G., Noy, Ariela, Maslak, Peter, Gencarelli, Alison N., Panageas, Katherine S., Heaney, Mark L., Brentjens, Renier J., Golde, David W., Scheinberg, David A., Zelenetz, Andrew D., Weiss, Mark A.
Publicado em 2009

Proposed Criteria for Response Assessment in Patients Treated in Clinical Trials for Myeloproliferative Neoplasms in Blast Phase (MPN-BP); Formal Recommendations from the Post-Myel...

por Mascarenhas, John, Heaney, Mark L, Najfeld, Vesna, Hexner, Elizabeth, Abdel-Wahab, Omar, Rampal, Raajit, Ravandi, Farhad, Petersen, Bruce, Roboz, Gail, Feldman, Eric, Podoltsev, Nikolai, Douer, Dan, Levine, Ross, Tallman, Martin, Hoffman, Ronald
Publicado em 2012

Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics

por Lee, Mona D., She, Yuhong, Soskis, Michael J., Borella, Christopher P., Gardner, Jeffrey R., Hayes, Paula A., Dy, Benzon M., Heaney, Mark L., Philips, Mark R., Bornmann, William G., Sirotnak, Francis M., Scheinberg, David A.
Publicado em 2004

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

por Rosenblat, Todd L., McDevitt, Michael R., Mulford, Deborah A., Pandit-Taskar, Neeta, Divgi, Chaitanya R., Panageas, Katherine S., Heaney, Mark L., Chanel, Suzanne, Morgenstern, Alfred, Sgouros, George, Larson, Steven M., Scheinberg, David A., Jurcic, Joseph G.
Publicado em 2010

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F

por Stein, Brady L., Oh, Stephen T., Berenzon, Dmitriy, Hobbs, Gabriela S., Kremyanskaya, Marina, Rampal, Raajit K., Abboud, Camille N., Adler, Kenneth, Heaney, Mark L., Jabbour, Elias J., Komrokji, Rami S., Moliterno, Alison R., Ritchie, Ellen K., Rice, Lawrence, Mascarenhas, John, Hoffman, Ronald
Publicado no J Clin Oncol (2015)

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinet...

por DeAngelo, Daniel J., Stone, Richard M., Heaney, Mark L., Nimer, Stephen D., Paquette, Ronald L., Klisovic, Rebecca B., Caligiuri, Michael A., Cooper, Michael R., Lecerf, Jean-Michel, Karol, Michael D., Sheng, Shihong, Holford, Nick, Curtin, Peter T., Druker, Brian J., Heinrich, Michael C.
Publicado em 2006

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

por Diamond, Eli L., Dagna, Lorenzo, Hyman, David M., Cavalli, Giulio, Janku, Filip, Estrada-Veras, Juvianee, Ferrarini, Marina, Abdel-Wahab, Omar, Heaney, Mark L., Scheel, Paul J., Feeley, Nancy K., Ferrero, Elisabetta, McClain, Kenneth L., Vaglio, Augusto, Colby, Thomas, Arnaud, Laurent, Haroche, Julien
Publicado em 2014

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

por Oh, Stephen T., Talpaz, Moshe, Gerds, Aaron T., Gupta, Vikas, Verstovsek, Srdan, Mesa, Ruben, Miller, Carole B., Rivera, Candido E., Fleischman, Angela G., Goel, Swati, Heaney, Mark L., O’Connell, Casey, Arcasoy, Murat O., Zhang, Yafeng, Kawashima, Jun, Ganz, Tomas, Kowalski, Mark, Brachmann, Carrie Baker
Publicado no Blood Adv (2020)

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

por Koppikar, Priya, Abdel-Wahab, Omar, Hedvat, Cyrus, Marubayashi, Sachie, Patel, Jay, Goel, Aviva, Kucine, Nicole, Gardner, Jeffrey R., Combs, Andrew P., Vaddi, Kris, Haley, Patrick J., Burn, Timothy C., Rupar, Mark, Bromberg, Jacqueline F., Heaney, Mark L., de Stanchina, Elisa, Fridman, Jordan S., Levine, Ross L.
Publicado em 2010

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

por Hobbs, Gabriela S., Hanasoge Somasundara, Amritha Varshini, Kleppe, Maria, Litvin, Rivka, Arcila, Maria, Ahn, Jihae, McKenney, Anna Sophia, Knapp, Kristina, Ptashkin, Ryan, Weinstein, Howard, Heinemann, Murk-Hein, Francis, Jasmine, Chanel, Suzanne, Berman, Ellin, Mauro, Michael, Tallman, Martin S., Heaney, Mark L., Levine, Ross L., Rampal, Raajit K.
Publicado no Haematologica (2018)

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

por Rampal, Raajit K., Mascarenhas, John O., Kosiorek, Heidi E., Price, Leah, Berenzon, Dmitriy, Hexner, Elizabeth, Abboud, Camille N., Kremyanskaya, Marina, Weinberg, Rona Singer, Salama, Mohamed E., Menghrajani, Kamal, Najfeld, Vesna, Sandy, Lonette, Heaney, Mark L., Levine, Ross L., Mesa, Ruben A., Dueck, Amylou C., Goldberg, Judith D., Hoffman, Ronald
Publicado no Blood Adv (2018)

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

por Mascarenhas, John O., Rampal, Raajit K., Kosiorek, Heidi E., Bhave, Rupali, Hexner, Elizabeth, Wang, Eunice S., Gerds, Aaron, Abboud, Camille N., Kremyanskaya, Marina, Berenzon, Dimitry, Odenike, Olatoyosi, Farnoud, Noushin, Krishnan, Aishwarya, Weinberg, Rona Singer, McGovern, Erin, Salama, Mohamed E., Najfeld, Vesna, Medina-Martinez, Juan S., Arango Ossa, Juan E., Levine, Max F., Zhou, Yangyu, Sandy, Lonette, Heaney, Mark L., Levine, Ross L., Mesa, Ruben A., Dueck, Amylou C., Hoffman, Ronald
Publicado no Blood Adv (2020)

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

por Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew T., O’Connell, Casey, Shammo, Jamile, Fleischman, Angela G., Scherber, Robyn M., Mesa, Ruben, Yacoub, Abdulraheem, Perkins, Cecelia, Meckstroth, Shelby, Behlman, Lindsey, Chiaramonte, Matthew, Salehi, Mahta, Ziadkhanpour, Kimia, Nguyen, Hellen, Siwoski, Olivia, Hung, Annie Kwok, Janania Martinez, Michelle, Nguyen, Jenny, Patel, Sagar, Kollipara, Revathi, Dave, Ami, Randall, Megan, Grant, Michael, Harrison, Mitchell, Fernandez Soto, Paola, Tremblay, Douglas, Hoffman, Ronald, Moshier, Erin, Mascarenhas, John
Publicado no Blood (2020)

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

por Leeksma, Alexander C., Taylor, Justin, Wu, Bian, Gardner, Jeffrey R., He, Jie, Nahas, Michelle, Gonen, Mithat, Alemayehu, Wendimagegn G., te Raa, Doreen, Walther, Tatjana, Hüllein, Jennifer, Dietrich, Sascha, Claus, Rainer, de Boer, Fransien, de Heer, Koen, Dubois, Julie, Dampmann, Maria, Dürig, Jan, van Oers, Marinus H. J., Geisler, Christian H., Eldering, Eric, Levine, Ross L., Miller, Vincent, Mughal, Tariq, Lamanna, Nicole, Frattini, Mark G., Heaney, Mark L., Zelenetz, Andrew, Zenz, Thorsten, Abdel-Wahab, Omar, Kater, Arnon P.
Publicado no Leukemia (2018)

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

por Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, Mascarenhas, John
Publicado no Lancet Haematol (2020)